semaglutide shortage 2023 fda status january 2025 Federal judge upholds FDA's removal of Ozempic, Wegovy from drug list GLP-1 No Longer on FDA's – Prescription fills for semaglutide dramatically

Neither the MHRA nor EMA recognise histamine intolerance as an adverse effect of tirzepatide in official product information or pharmacovigilance data

These symptoms may indicate peripheral vascular issues, particularly relevant for patients with diabetes who have increased cardiovascular risk

Many commercial plans now cover FDA-approved obesity medications (Wegovy, Saxenda) with prior authorization

Oral (Rybelsus) requires fasting, max 4 oz water, 30-min wait

Unopened pens remain stable until the printed expiry date when refrigerated at 2C to 8C, typically providing approximately 30 months' shelf life from manufacture

Enriched with skin-loving ingredients